Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – September 2019 on Thursday, November 7, 2019 at 07:30 a.m. CET.
Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on November 7, at 13:00 – 14:00 p.m CET.
Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Interim Report Report for the period January – September 2019 followed by a Q&A-session.
To participate, please call any of the following phone numbers from:
|Sweden:||+ 46 8 566 427 05|
|UK:||+ 44 333 300 9262|
|US:||+ 1 833 823 0586|
For more information, please contact:
Anders Lundin, CFO, Q-linea AB
+46 (0)70-600 15 20
The information was submitted for publication at 13:00 CET on October 31, 2019.
Q-linea is an innovative research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar™ is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.